Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sublingual liraglutide
- Development stage
- Unknown
- Lead developer
- Biolingus
- Modality
- Peptides
- Administration
- Sublingual
01
Overview
Sublingual liraglutide is a biobetter formulation of the GLP-1 receptor agonist liraglutide, developed by **Biolingus** using its proprietary **OPUS (Oral Peptide Ultra-fast System)** technology. This formulation is designed for non-invasive sublingual administration, providing a patient-friendly alternative to the standard subcutaneous injections (such as Victoza). Liraglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking endogenous GLP-1 to enhance glucose-dependent insulin secretion, suppress inappropriate glucagon release, and slow gastric emptying. The sublingual delivery system utilizes specific stabilization and transport mechanisms to allow the peptide to cross the sublingual mucosa effectively. It is currently being evaluated in Phase Ib/IIa clinical trials for the treatment of type 2 diabetes mellitus and is also in development for obesity.
- Other names
- SL liraglutidesublingual liraglutide BiolingusBiolingus liraglutide
02
Targets
Beyond the preview
Go deeper on sublingual liraglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sublingual liraglutide.